

The 4th Nordic RWE Conference 2020

— in collaboration with the
Oslo Life Science Conference

Tuesday February 11th 09.00-16.00

Kaare Norum-salen, Oslo Cancer Cluster,
Ullernchausseen 64 in Oslo — [Map](#)

Focusing on RWD for clinical drug development, RWE for health tech assessment and implementation of new drugs, the 4th Nordic RWE Conference is arranged as part of the Oslo Life Science Conference and highlights RWE initiatives spearheaded by the Nordics.

As the event is collaborating with Oslo Life Science Conference, participants are also invited to join the [welcome reception in the City Hall](#), the [Main Oslo Life Science](#) event as well as the [Personalized Cancer therapy event](#), which runs simultaneously with this event's breakout-sessions. Please see the full program below for additional details. Moderator: Erik Hjelvin, Medical director, Pfizer

PROGRAM

09:00 – 09.10

Welcome an opening remarks

Monica Larsen, Senior adviser, The Norwegian Pharma Association

KEYNOTE SPEAKERS

09:10 – 09.40

How RWE is changing the landscape for drug development and clinical use in Europe

Thomas Senderovitz, Director General of the Danish Medicines Agency, Chair of the HMA Management Group

09.40 – 10.00

Current Challenges in the Use of Evidence and Insights from RWD
Virginia Acha, MSD, and EFPIA Evidence Generating Working Group

10.00 – 10.20

Registry-based randomized clinical trials—a new clinical trial paradigm

Stefan James, Professor Department of Medical Science, Akademiska sjukhuset, Uppsala

RWE INITIATIVES THAT PUT THE NORDIC REGION IN THE FOREFRONT

10.20 – 10.40

The Norwegian Health analytic platform

Marianne Braaten, Project leader, The Norwegian Directorate of eHealth

10.40– 11.00

INSPIRE – A Pilot project to capture cancer medication data from hospitals

Lena Holmström, special advisor, the Cancer Registry of Norway

11.00 – 11.20

Secondary use of health data – Findata, the new one-stop-shop

Johanna Seppänen, PhD, Director, Social and Health Data Permit Authority Findata

11.20 – 11.40

Status of secondary use of Danish health data – including New registries relevant for research and RWE

Jan Poulsen, Head of Department, The Danish Health Data Authority

11.40 – 12.00

Implementing a clinical decision support system within Swedish cancer care

Maria Sørbo, Regionala CancerCentrum, Uppsala

12.00 – 13.00

LUNSI

BREAKOUT SESSIONS 13.00-15.15

Participants are also welcome to attend parallel sessions with the event
Personalized cancer therapy

	RWD IN RESEARCH AND DEVELOPMENT Moderator: Pål Hasvold, Medical Evidence Director, AstraZeneca	RWE FOR REIMBURSEMENT AND HEALTHCARE DECISION MAKING Moderator: Nikolaus Oberprieler, Scientific Advisor (srMSL) and Epidemiology, Bayer
13.00	Electronic Health Records for Clinical Research (EHR4CR) - Where are we now, and how to include the Nordics? In-Site and Trinext tools Mats Sundgren, (EHR4CR Coordinator), Principal Scientist at AstraZeneca R&D	RWE in Regulatory and health care decision making Jens Torup Østby, Patient & Health Impact International, Pfizer
13.20	Finnish big data lakes for better healthcare and research - from discovery to feasibility studies Samu Kurki, Senior data scientist, Auria Biobank, Turku, Finland	Experience with RWE within Inflammatory Bowel Disease in Norway, -the TRIN study Borghild Sæbø, Medical Advisor, Takeda AS
13.40	External control arms in clinical trials Jessica Davies, Principal Data Scientist, RWD Collaborations, PHC Data Science team at Roche	12 min. pitch from: Real-world evidence for health economic purposes Erkki Soini, CEO, Health Economist ESioR Oy
14.00	Genomic Medicine Sweden - a national infrastructure for better diagnostics, treatment and research Mikaela Friedman, PhD Research Coordinator, Karolinska Institutet, Dept. of Molecular Medicine and Surgery (MMK) Genomic Medicine Sweden	Building a world class infertility monitoring system, Marjukka Suomela, Ferring Oy - Lisse-Lotte Hermansson, BCB Medical Ltd.
14.20	Using artificial intelligence for the design of personalized cancer immunotherapy Richard Stratford Ph.D. CEO NEC Oncolmmunity	How RWE enables the change from general effectiveness to country specific effectiveness Mattias Kyhllstedt, CEO and founder of Synergus RWE
14.40	Visions and practical work going on in the new "Science Center" focusing on health data, RWD and RWE Arun Micheelsen DLI MI, Jacob Bjerg Larsen, LIF Dk	Daily medical real men benchmarking and quality registers in one work flow Tone Speilberg Birkenes, Managing Director, DiaGraphIT® AS RWE in HTA and beyond Jarmo Hahl, CEO, Medaffcon Oy Way to success: RWD + PRO = RWE Heli Salminen-Mankonen, Leader, Real World Evidence, PhD, Dos., eMBA, Oriola

15.15- 15.30

Report from the breakouts by the Moderators

15.30 - 16.00

Panel discussion

How can information from RWD impact decision making in the healthcare system
Moderator: Jan Anders Istad, MScPharm, Head of Public Affairs Novartis

Participants (TBD)

Virginia Acha, MSD, and EFPIA Evidence Generating Working Group
Karen Marie Ulshagen, Director Timely access, Norwegian Medicines Agency
Jan Poulsen, Head of Department, The Danish Health Data Authority
Karolina Antonov, Head of Strategy, Pharma Industry Sweden
Johanna Seppänen, PhD, Director, Social and Health Data Permit Authority Findata

PARTNERS

Lääketeollisuus
Pharma Industry Finland

LMI



OsloLifeScience



NordForsk



Nordplus

SPONSORS



 **NOVARTIS**

AstraZeneca 

